CTLA4 and head and neck squamous cell carcinoma: Subsequently, we explored the relationship between three scores and known immunotherapy predictive signatures PD-1, PD-L1, CTLA-4, and TMB, which was evaluated in prospective clinical trials as a potential signature for predicting immune checkpoint inhibitor therapy response in HNSCC (Cristescu et al., 2018; Chan et al., 2019).